American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

被引:291
作者
Kyle, Robert A.
Yee, Gary C.
Somerfield, Mark R.
Flynn, Patrick J.
Halabi, Susan
Jagannath, Sundar
Orlowski, Robert Z.
Roodman, David G.
Twilde, Patricia
Anderson, Kenneth
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Rochester, MN USA
[3] Minnesota Oncol Hematol PA, Minneapolis, MN USA
[4] St Vincents Comprehens Canc Ctr, New York, NY USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Univ N Carolina, Chapel Hill, NC USA
[7] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[8] Univ Nebraska Med Ctr, Omaha, NE USA
关键词
D O I
10.1200/JCO.2007.12.1269
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ). Methods For the 2007 update, an Update Committee composed of members from the full panel completed a review and analysis of data published since 2002. Searches of Medline and the Cochrane Collaboration Library databases were performed. Recommendations For multiple myeloma patients who have, on plain radiograph(s) or imaging studies, lytic destruction of bone or spine compression fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Clodronate is an alternative bisphosphonate approved worldwide, except in the United States, for oral or intravenous administration. New dosing guidelines for patients with pre-existing renal impairment were added to the zoledronic acid package insert. Although no similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The Update Committee suggests that bisphosphonate treatment continue for a period of 2 years. At 2 years, physicians should seriously consider discontinuing bisphosphonates in patients with responsive or stable disease, but further use is at the discretion of the treating physician. The Update Committee also discusses measures regarding ONJ.
引用
收藏
页码:2464 / 2472
页数:9
相关论文
共 45 条
[1]   Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis [J].
Aguiar Bujanda, D. ;
Bohn Sarmiento, U. ;
Cabrera Suarez, M. A. ;
Aguiar Morales, J. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :556-560
[2]  
*AM ASS END POS ST, END IMPL BISPH ASS O
[3]   Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].
Attal, Michel ;
Harousseau, Jean-Luc ;
Leyvraz, Serge ;
Doyen, Chantal ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Agha, Ibrahim Yakoub ;
Bourhis, Jean-Henri ;
Garderet, Laurent ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Renaud, Marc ;
Voillat, Laurent ;
Berthou, Christian ;
Marit, Gerald ;
Monconduit, Mathieu ;
Caillot, Denis ;
Grobois, Bernard ;
Avet-Loiseau, Herve ;
Moreau, Philippe ;
Facon, Thierry .
BLOOD, 2006, 108 (10) :3289-3294
[4]   Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[5]   Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases [J].
Bagan, JV ;
Murillo, J ;
Jimenez, Y ;
Poveda, R ;
Milian, MA ;
Sanchis, JM ;
Silvestre, FJ ;
Scully, C .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (02) :120-123
[6]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[7]   Podocyte injury associated glomerulopathies induced by pamidronate [J].
Barri, YM ;
Munshi, NC ;
Sukumalchantra, S ;
Abulezz, SR ;
Bonsib, SM ;
Wallach, J ;
Walker, PD .
KIDNEY INTERNATIONAL, 2004, 65 (02) :634-641
[8]  
Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO
[9]  
2-0
[10]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493